MC3R and brain neoplasm: The quantitative results showed that the MFI of brain tumors in the VIP group was reduced by 18.88% at 3 d and 32.71% at 6 d after administration compared with the MC3 group (Supplementary Fig. S17b, c), showing the potential of delivering therapeutic siRNA drugs to brain tumors.